Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Minerva Neurosciences' stock, expecting it to reach $7 in value.
Financial Health
Minerva Neurosciences is showing strong cash generation, which is a positive sign for investors.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NERV
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
CNS‑focused pipeline
The company targets central nervous system conditions, so investors often focus on clinical progress and scientific rationale — though trial outcomes can be uncertain.
Clinical readouts ahead
Upcoming trial results and regulatory steps can materially affect valuation. Positive data may lift sentiment, while negative outcomes can be swift and severe.
Small‑cap dynamics
With a modest market capitalisation, the stock may experience high volatility and low liquidity; financing needs could also lead to dilution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
